Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. [electronic resource]
Producer: 19980612Description: 3662-70 p. digitalISSN:- 0006-4971
- Adult
- Amyloidosis -- drug therapy
- Antineoplastic Agents, Alkylating -- administration & dosage
- Cohort Studies
- Combined Modality Therapy
- Erythrocyte Transfusion
- Female
- Hematopoietic Stem Cell Transplantation -- adverse effects
- Humans
- Kidney -- pathology
- Life Tables
- Liver -- pathology
- Male
- Melphalan -- administration & dosage
- Middle Aged
- Myocardium -- pathology
- Nervous System -- pathology
- Paraproteins -- analysis
- Platelet Transfusion
- Prognosis
- Recurrence
- Severity of Illness Index
- Survival Analysis
- Transplantation Conditioning
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
There are no comments on this title.
Log in to your account to post a comment.